<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838487</url>
  </required_header>
  <id_info>
    <org_study_id>ZODIAC</org_study_id>
    <nct_id>NCT00838487</nct_id>
  </id_info>
  <brief_title>Evaluate Safety &amp; Efficacy of Condroflex in Subjects With OA</brief_title>
  <acronym>ZD20108</acronym>
  <official_title>Phase 3 Study, to Evaluate Safety &amp; Efficacy of the Association Condroflex + Therapeutic Exercises Compared to Placebo + Therapeutic Exercises, in Subjects With Knee OA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zodiac Produtos Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zodiac Produtos Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the
      improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western
      Ontario and McMaster Universities Arthritis Index), achieved with Condroflex ® oral
      administration(sulfate glucosamine + chondroitin sulfate sodium) in association with
      therapeutic exercises, compared to placebo in association with therapeutic exercises in
      individuals with knee OA and not exposed to prior treatment with the products under
      investigation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To have osteoarthritis degree 2 or 3 / To be capable to consent
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of pain</measure>
    <time_frame>12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rigidity restriction</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Treatment</condition>
  <condition>Osteoarthritis</condition>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>condroflex and exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>assent arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill and exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>condroflex and exercise</intervention_name>
    <description>1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week</description>
    <arm_group_label>condroflex and exercise</arm_group_label>
    <other_name>glucosamine sulph + chondroitin sulph and therapeutic exerc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sugar pill and exercise</intervention_name>
    <description>1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week</description>
    <arm_group_label>sugar pill and exercise</arm_group_label>
    <other_name>Placebo Comparator and therapeutic exerc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  to have knee osteoarthritis degree 2 or 3

          -  to be capable to consent

        Exclusion Criteria:

          -  previous drug treatment

          -  concomitant diseases

          -  concomitant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suely Roizenblatt</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRM Regional Council of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suely Roizenblatt</last_name>
    <phone>55 11 5908-7081</phone>
    <email>suelyroi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magda Bignotto</last_name>
    <phone>55 11 5908-7081</phone>
    <email>magda@afip.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRDB</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suely Roizenblatt, Dra.</last_name>
      <phone>55 11 5908-7081</phone>
      <email>suelyroi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Magda Bgnotto, Dra.</last_name>
      <phone>55 11 5908-7081</phone>
      <email>magda@afip.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Suely Roizenblatt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>October 9, 2009</last_update_submitted>
  <last_update_submitted_qc>October 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Julio Cesar Nophal de Carvalho</name_title>
    <organization>Zodiac Produtos Farmaceuticos</organization>
  </responsible_party>
  <keyword>chondroitin</keyword>
  <keyword>glucosamine</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

